HSIN-YUN SUNCheng, Chien-YuChien-YuChengLin, Chi-YingChi-YingLinYang, Chia-JuiChia-JuiYangLee, Nan-YaoNan-YaoLeeLiou, Bo-HuangBo-HuangLiouTang, Hung-JenHung-JenTangLiu, Yuang-MengYuang-MengLiuLee, Chun-YuanChun-YuanLeeChen, Tun-ChiehTun-ChiehChenYI-CHIA HUANGLee, Yuan-TiYuan-TiLeeMING-JUI TSAILu, Po-LiangPo-LiangLuTsai, Hung-ChinHung-ChinTsaiWang, Ning-ChiNing-ChiWangHung, Tung-CheTung-CheHungCheng, Shu-HsingShu-HsingChengCHIEN-CHING HUNG2022-05-252022-05-252022-03-2110079327https://scholars.lib.ntu.edu.tw/handle/123456789/612038Hepatitis C virus (HCV) genotype 6 (HCV-6) infection is prevalent predominantly in Southeast Asia, and the data on the virologic response of HCV-6 to direct-acting antivirals (DAAs) are sparse in people living with human immunodeficiency virus (HIV) (PLWH).enAntiretroviral therapy; End-of-treatment response; People who inject drugs; Sustained virologic response; Tenofovir; Viral hepatitis[SDGs]SDG3Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infectionsjournal article10.3748/wjg.v28.i11.1172354315052-s2.0-85127423575https://scholars.lib.ntu.edu.tw/handle/123456789/604294